



OPEN ACCESS

## CASE REPORT

## Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose

Théo Korchia,<sup>1</sup> Graham Blackman,<sup>2</sup> Michel Cermolacce,<sup>1</sup> Raphaëlle Richieri<sup>1,2,3</sup><sup>1</sup>Department of Psychiatry, Assistance Publique Hopitaux de Marseille, Marseille, France<sup>2</sup>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK<sup>3</sup>Institut Fresnel - UMR 7249, Faculté des Sciences de Saint Jérôme, Marseille, France**Correspondence to**

Dr Raphaëlle Richieri, raphaelle.richieri-le\_rouzic@kcl.ac.uk

Accepted 14 July 2018

**SUMMARY**

Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse drug reaction. We report a case of NMS potentially induced by dehydration in a female patient suffering from schizoaffective disorder. We discuss possible aetiologies and triggering factors alongside the existing literature.

**BACKGROUND**

Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse drug reaction that affects 0.2% to 3.2% of psychiatric inpatients.<sup>1</sup> Despite being a well-recognised condition, the pathogenesis of NMS is not fully understood. Although many risk factors have been identified, predicting which patients will develop NMS and when, remains extremely difficult.<sup>2</sup> We report a case of NMS and discuss possible aetiologies with reference to the existing literature.

**CASE PRESENTATION**

A 57-year-old woman with an established diagnosis of schizoaffective disorder was admitted to the emergency department following an attempted suicide by taking an overdose of cyamemazine 750 mg (a first-generation antipsychotic of the phenothiazine class) and lercanidipine 300 mg (an antihypertensive of the dihydropyridine class of calcium channel blockers) tablets.

She had a medical history of obesity (body mass index 33 kg/m<sup>2</sup>), obstructive sleep apnoea, cholecystectomy, well-controlled hypertension, type 2 diabetes and hyperlipidaemia and was prescribed bisoprolol, lercanidipine, atorvastatin and metformin. For management of her schizoaffective symptoms, she was prescribed zuclopenthixol decanoate 300 mg monthly (a long-acting injectable antipsychotic) and cyamemazine 50 mg daily.

She was asymptomatic on arrival to the emergency department, however subsequently developed vasoplegic syndrome requiring admission to intensive care unit (ICU) and treatment with intravenous norepinephrine 4 mg/hour for hypotension. After a 3-day medical admission, she was transferred to a psychiatric ward.

**Investigations**

On admission to the psychiatric ward, she presented as depressed with mild anxiety and psychomotor agitation, with no evidence of suicidal ideation or psychotic symptoms. Blood tests were normal, except for persistently deranged liver function tests

(aspartate aminotransferase, AST=59 IU/L; alanine aminotransferase, ALT=30 IU/L). Zuclopenthixol decanoate was continued, and cyamemazine (25 mg to 75 mg daily) was restarted for antipsychotic prophylaxis. Escitalopram (10 mg daily) was started for treatment of depressive symptoms.

Five weeks into her admission on a psychiatric ward, a medication administration error occurred and instead of receiving zuclopenthixol decanoate, she was given 100 mg zuclopenthixol acetate intramuscularly (the short-acting form of the drug). The following day, she presented with acute confusion, which continued for 6 days. There was no evidence of hyperthermia, autonomic dysfunction, raised creatine kinase (CK) or white cell count (WCC). Zuclopenthixol was paused for 2 months before being restarted in tablet form (zuclopenthixol dihydrochloride; titrated from 5 to 40 mg daily over 2 weeks). Cyamemazine was continued at a low dose (50 mg to 100 mg daily) before being discontinued a week before the reintroduction of zuclopenthixol. The reintroduction of zuclopenthixol was initially well tolerated and led to an improvement in her anxiety and depressive symptoms.

Two weeks after restarting zuclopenthixol, she was noted to be clinically dehydrated with dry mucous membranes and reduced skin elasticity. Biochemical analysis revealed increased serum creatinine (141 µmol/L) and hypernatraemia (151 mmol/L), and she was commenced on intravenous fluids. Two days later, she developed confusion with stupor, hyperthermia (39.4°C), persistent hypertension (160/98 mm Hg) and severe muscle rigidity. She was transferred to ICU where blood tests revealed deranged CK (6326 IU/L), WCC (14 000/mm<sup>3</sup>), sodium (153 mmol/L), creatinine (117 µmol/L), fibrinogen (551 g/L) and evidence of hepatic cytolysis (AST=158 IU/L and ALT=76 IU/L). Electroencephalograms, head CT scan, lumbar puncture, blood cultures and urinalysis were all unremarkable.

**OUTCOME AND FOLLOW-UP**

A clinical diagnosis of NMS was made. All antipsychotics were discontinued, and she spent a 10-day period on ICU where she received rehydration therapy, muscle relaxants and regular benzodiazepines (oxazepam 30 mg daily) leading to full resolution of her neurological symptoms and confusion. After being transferred back to a psychiatry ward, she was not restarted on antipsychotic medication but was instead treated with a course of electroconvulsive therapy. This led to a significant improvement in her psychotic symptoms by the third session



© BMJ Publishing Group Limited 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Korchia T, Blackman G, Cermolacce M, et al. *BMJ Case Rep* Published Online First: [please include Day Month Year]. doi:10.1136/bcr-2017-223922

(20 days after the onset of NMS). At follow-up, 11 months after the onset of NMS, she remained neurologically intact and her schizoaffective symptoms remained partially controlled on maintenance electroconvulsive therapy (ECT) without antipsychotic medication.

### DISCUSSION

We describe a case of NMS occurring in a patient with schizoaffective disorder after receiving excessive amounts of antipsychotic medication on two occasions within a 6-week period: the first in the context of an attempted suicide and the second following an accidental overdose due to an administration error.

According to Diagnostic and Statistical Manual of Mental Disorders (DSM-5), diagnosis of NMS requires a patient to meet the following major criteria: (1) exposure to a dopamine blocking agent, (2) severe muscle rigidity and (3) fever, and at least 2 of 10 minor criteria.<sup>3</sup> Our patient presented all of the major criteria, and seven of the minor criteria (raised CK, diaphoresis, tachycardia, increased blood pressure and heart rate, altered consciousness and leucocytosis). While the patient clearly displayed the classic features indicative of NMS, there are several atypical aspects of the case worthy of discussion.

Notably, the patient did not develop NMS until 2 months after the iatrogenic overdose of zuclopenthixol. This is surprising given that maximum serum concentration following intramuscular injection of zuclopenthixol acetate occurs after 24–48 hours, and plasma elimination half life is approximately 20 hours.<sup>4</sup> Further, around the time of the medication error, additional risk factors for NMS were present, including concomitant treatment with two first-generation antipsychotics and psychomotor agitation.<sup>1,5</sup> Instead, NMS occurred later while being prescribed a single antipsychotic (zuclopenthixol dihydrochloride) at a low dose.

In the present case, acute renal failure (ARF) and hepatic cytolysis were not the sequelae of NMS. Rather, they predated NMS, and therefore may have played a causative role<sup>2,6</sup> by impairing the metabolism and excretion of zuclopenthixol leading to elevated serum concentrations of the drug. Also of note, escitalopram, which is a cytochrome P450 2D6 enzyme inhibitor, was prescribed at the time NMS developed, and therefore may have contributed towards raised serum concentrations of zuclopenthixol.

The pathogenesis of NMS can be considered a complex cascade of dysregulation of multiple neurochemical and neuroendocrine systems, culminating in an end-stage hypermetabolic syndrome.<sup>7</sup> A central dopaminergic blockade theory has been proposed to explain NMS involving striatal and hypothalamic dopamine receptors.<sup>8</sup> There is also evidence to suggest that dysregulation of the sympathetic nervous system may account for, at least some of, the features of NMS.<sup>9</sup> Finally, more recently a neuroimmunological explanation of NMS has been proposed, implicating the role of proinflammatory cytokines.<sup>10</sup> In our case report, the elevation of fibrinogen (an acute phase protein) is consistent with this later hypothesis, with the patient's dehydration potentially acting as an inflammatory stimulus.

This case report highlights the importance of recognising that patients may develop NMS several years after starting antipsychotic therapy. Furthermore, NMS may occur any time, but particularly in the presence of additional risk factors, such as dehydration. ARF in the presence NMS is associated with a mortality risk of approximately 50%,<sup>11</sup> therefore, it is vital that clinicians are vigilant for evidence of dehydration in patients treated with antipsychotics.

### Patient's perspective

The ECT allowed me to resume activities that I had not been doing for several years as dancing, seeing friends, playing cards and improved substantially my quality of life.

### Learning points

- ▶ Neuroleptic malignant syndrome (NMS) is a serious and potentially lethal adverse drug reaction.
- ▶ NMS is unpredictable but is related to the administration of dopamine antagonists.
- ▶ NMS can be best described as a complex cascade of multiple dysregulated neurochemical and neuroendocrine systems, potentially culminating in an end-stage hypermetabolic syndrome.
- ▶ Risk factors for NMS, such as dehydration as well as renal and hepatic impairment, should be considered prior to, and during treatment with antipsychotics.

**Acknowledgements** The authors thank the patient for her understanding and permission to publish her case.

**Contributors** TK, MC, RR: contributed to the acquisition or interpretation of data. TK, GB, MC, RR: drafted the work or revised it critically for important intellectual content. TK, GB, MC, RR: read the final version of this manuscript, approve its content and submission for publication. TK, GB, MC, RR: agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### REFERENCES

- 1 Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. *Psychiatr Serv* 1998;49:1163–72.
- 2 Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. *Curr Neuropharmacol* 2015;13:395–406.
- 3 American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5th edn. Washington, DC: American Psychiatric Publishing, 2013.
- 4 [https://www.lundbeck.com/upload/ll/files/pdf/patient\\_and\\_doctor\\_information/Clopixol\\_Acuphase\\_leafelt\\_pcr\\_approval.pdf](https://www.lundbeck.com/upload/ll/files/pdf/patient_and_doctor_information/Clopixol_Acuphase_leafelt_pcr_approval.pdf)
- 5 Viejó LF, Morales V, Puñal P, et al. Risk factors in neuroleptic malignant syndrome. A case-control study. *Acta Psychiatr Scand* 2003;107:45–9.
- 6 Ninčević Ž, Lasić D, Glavina T, et al. Quetiapine poisoning associated with neuroleptic malignant syndrome, rhabdomyolysis and renal failure: a case report. *Psychiatr Danub* 2017;29:84–6.
- 7 Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. *Drugs R D* 2015;15:45–62.
- 8 Levenson JL. Neuroleptic malignant syndrome. *Am J Psychiatry* 1985;142:1137–45.
- 9 Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. *Am J Psychiatry* 1999;156:169–80.
- 10 Anglin RE, Rosebush PI, Mazurek MF. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. *CMAJ* 2010;182:E834–E838.
- 11 Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. *J Clin Psychiatry* 1989;50:18–25.

Copyright 2018 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <http://group.bmj.com/group/rights-licensing/permissions>.

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact [consortiasales@bmjgroup.com](mailto:consortiasales@bmjgroup.com)

Visit [casereports.bmj.com](http://casereports.bmj.com) for more articles like this and to become a Fellow